Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC).
2014 ◽
Vol 32
(15_suppl)
◽
pp. 633-633
Keyword(s):
Phase Ii
◽
2015 ◽
Vol 372
(2)
◽
pp. 134-141
◽
Keyword(s):
2021 ◽
2019 ◽
Vol 17
(1)
◽
pp. 47-56
◽
Keyword(s):
Keyword(s):
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours
2009 ◽
Vol 20
(4)
◽
pp. 373-375
2014 ◽
Vol 21
(11)
◽
pp. 3490-3496
◽